Search Results - "Squier, Peg"

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment by Yeleswaram, Swamy, Smith, Paul, Burn, Timothy, Covington, Maryanne, Juvekar, Ashish, Li, Yanlong, Squier, Peg, Langmuir, Peter

“…Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid…”
Get full text

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL by Gerds, Aaron T., Mesa, Ruben, Burke, John M., Grunwald, Michael R., Stein, Brady L., Squier, Peg, Yu, Jingbo, Hamer-Maansson, J. E., Oh, Stephen T.

“…•REVEAL is a prospective observational study that enrolled 2510 patients with PV, with median follow-up of 44.7 months (range, 2-59 months).•Acute and…”
Get full text

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies by Verstovsek, Srdan, Kiladjian, Jean‐Jacques, Vannucchi, Alessandro M., Mesa, Ruben A., Squier, Peg, Hamer‐Maansson, J. E., Harrison, Claire

“…Background In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT‐I) and COMFORT‐II clinical trials,…”
Get full text

Outcomes by schedule and line of therapy in patients (pts) with metastatic breast cancer (MBC) treated with nab -paclitaxel ( nab -P): A U.S. retrospective, community-based, real-world cohort analysis by Patt, Debra A., Stergiopoulos, Sotirios G., Hippert, Rick, Harrell, Robyn K., Espirito, Janet L., Squier, Peg, Ko, Amy

“…Abstract only 86 Background: In a phase III study in MBC, nab-P showed activity across lines of therapy. nab-P is approved for MBC at 260 mg/m 2 every 3 weeks…”
Get full text

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm by Langmuir, Peter, Yeleswaram, Swamy, Smith, Paul, Knorr, Barbara, Squier, Peg

“…Recent insight into the pathophysiology of severe coronavirus disease 2019 (COVID-19) has implicated hyperactivation of the immune response, resulting in a…”
Get full text